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Abstract 
 
The phenotypes of mitochondrial diseases caused by mutations in mitochondrial 
DNA (mtDNA) have been proposed to be strictly regulated by the proportion of 
wild-type and pathogenically mutated mtDNAs.  More specifically, it is thought that 
the onset of the disease phenotype occurs when cells cannot maintain the proper 
mitochondrial function because of an over-abundance of pathological mtDNA.  
Therapies that cause a decrease in the pathogenic mtDNA population have been 
proposed as a treatment for mitochondrial diseases, but these therapies are difficult to 
apply in practice.  In this report, we present a novel concept: to improve mitochondrial 
disease phenotypes via an increase in the absolute copy number of the wild-type 
mtDNA population in pathogenic cells even when the relative proportion of mtDNA 
genotypes remains unchanged.  We have succeeded in ameliorating the typical 
symptoms of mitochondrial disease in a model mouse line by the over-expression of the 
mitochondrial transcription factor A (Tfam) followed by an increase of the mtDNA 
copy number.  This new concept should lead to the development of a novel therapeutic 
treatment for mitochondrial diseases. 
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Introduction 
 
Mitochondria play several essential roles in cell functions, and the accumulation of 
mitochondrial DNA (mtDNA) with pathogenic mutations causes mitochondrial diseases, 
including mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes (MELAS); myoclonus epilepsy with ragged red fibers (MERRF); 
Kearns-Sayre syndrome (KSS); and chronic progressive external ophthalmoplegia 
(CPEO) [1,2]. 
One general feature of mitochondrial diseases is that at least two types (wild-type 
and mutated) of mtDNA exist in a single cell, which is a genetic status called 
heteroplasmy.  Several mouse models have been generated to study human 
mitochondrial diseases, including heteroplasmic mtDNA genetics.  These mice possess 
mtDNAs derived from two strains [3,4] containing either point-mutated mtDNA [5,6] 
or mtDNA that has a large deletion [7].  These mice have been used to study mtDNA 
transmission, pathogenic mechanisms, and the development of an effective therapies for 
diseases.  Effective treatment procedures for diseases have not yet been established, 
although several attempts have been reported, including a study in which one type of 
mtDNA (presumably pathogenic) was specifically digested by a mitochondrial-targeted 
restriction enzyme [8].  However, this treatment is difficult to apply practically to 
medical care because the restriction sites specific to the pathogenic mutant on the 
mtDNA are rare. 
Mitochondrial diseases are caused by the accumulation of mtDNA with pathogenic 
mutations in single cells followed by the reduction of mitochondrial respiration activity.  
Interestingly, this reduction of activity does not simply and linearly correlate with the 
proportion of mutated mtDNA but is caused only when the proportion of the mutated 
mtDNA exceeds a certain threshold level [7,9,10].  This phenomenon is thought to be 
caused by the occurrence of inter-mitochondrial complementation through the mixing of 
genetic contents [10] due to mitochondrial dynamics, such as fusion, fission and 
transportation [11] that makes mitochondria function as a single cellular unit [12].  The 
accumulation of mutated mtDNA causes a decrease in wild-type mtDNA, which results 
in a reduction of genetic factors and defects in respiratory activity. 
The depletion of mtDNA copy number in humans [13] and mice [14] has caused 
severe diseases, such as mtDNA depletion syndrome (MDS).  Furthermore, the 
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down-regulation of mtDNA replication or transcription by knockout [15] or knockdown 
[16] of the Tfam gene, which encodes the mtDNA binding protein, results in decreased 
respiratory activity.  These data suggest that an appropriate copy number of normal 
mtDNA is essential for the maintenance of mitochondrial function and that cells 
carrying mutated mtDNA may be rescued by the increase of wild-type mtDNA 
sufficient to supply normal rRNAs, tRNAs and proteins. 
Based on this view, we generated transgenic mice that over-express Tfam to increase 
the total mtDNA copy number [17,18], and we mated these mice to the mitochondrial 
diseases model mice (mito-mice) with mutant mtDNA carrying a deletion of 4696 bp 
(#mtDNA) [7].  The increase in total mtDNA copy number due to the over-expression 
of Tfam in the mito-mice improved the severe symptoms of mitochondrial disease 
exhibited by the mito-mice, resulting in a prolonged life span.  From this study, we 
propose a novel therapeutic treatment for mitochondrial diseases. We propose that an 
increase in the absolute copy number of healthy mtDNA restores the normal 
mitochondrial function even under conditions where the proportion of pathogenic 
mtDNA is unchanged. 
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Materials and methods 
 
Mouse strains 
The C57BL/6J (CLEA Japan), mito-mouse [7] and Tfam/EGFP-Tg strains were 
used in this research.  The Institutional Animal Experiment Committee approved all of 
the animal experiments. 
 
Estimation of mtDNA copy number by comparative real-time PCR 
Comparative real-time PCR for estimating the copy number of mtDNA in the 
tissues of mito-mice and Tg-mito-mice was performed using a QuantiTect SYBR Green 
PCR Kit (Qiagen) with Gapdh as the control for the nuclear genome copy number.  
The following primers were used: 5$- AAC TCA AAG GAC TTG GCG GTA CTT 
TAT ATC-3$ and 5$- GAT GGC GGT ATA TAG GCT GAA TTA GCA AGA G-3$ to 
amplify the region common in both the wild-type and the deleted mtDNA, and 5$-AAC 
GAC CCC TTC ATT GAC-3$ and 5$-TCC ACG ACA TAC TCA GCA C-3$ for Gapdh 
[19]. 
The total DNA samples purified from the tissues were diluted to a concentration of 
100 pg/µl - 1000 pg/µl and amplified using an ABI Prism 7900 (Applied Biosystems).  
The thermal cycling conditions were as follows: 50°C for 2 min; 95°C for 15 min; and 
40 cycles of 95°C for 20 sec followed by 60°C for 60 sec. 
 
Estimation of #mtDNA proportions by real-time PCR 
Real-time PCR was used to estimate the proportions of #mtDNA, as previously 
described [20]. 
 
Northern blot for mitochondrial tRNA 
Total RNA was purified from homogenized tissue samples using ISOGEN 
(NIPPON GENE), and Northern blots were then carried out as previously described 
[21,22].  The DNA sequences for the specific probes were as follows: 5’- ATG TTT 
TTA AAC ATG GAA GCA TGA A-3’ for tRNASer(AGY) and 5’- GTC TCC CAT CCA 
AGT ACT AAC CAA G-3’ for 5S rRNA. 
 
BUN measurement 
6 
Blood was obtained from a tail vein, and blood urea nitrogen (BUN) concentrations 
were measured using a Urea N B kit (Wako Pure Chemical) as previously described 
[23]. 
 
Histochemical analyses of COX and SDH activity 
Histochemical analyses of cytochrome c oxidase (COX) and succinate 
dehydrogenase (SDH) activity were carried out as previously described [7,10].  Hearts 
and kidneys were excised from the animals, and 10-µm cryosections from the tissues 
were stained for COX and SDH activity. 
 
Single-fiber PCR analysis 
Two serial 10-%m cryosections of heart muscle were used for single-fiber PCR.  
One of the sections was stained for COX and SDH activity, and the COX-positive fibers 
were selected for PCR analysis.  Another section was used for the dissection of the 
cytoplasm corresponding to the COX-positive fibers with an LMD6000 (Leica).  The 
total DNA was extracted from dissected samples and used directly for PCR analysis as 
previously described [24].  The PCR conditions were also carried out as described 
above. 
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Results 
 
Tfam/EGFP over-expression increased the amount of mtDNA 
We generated a transgenic (Tg) mouse strain that over-expressed the mtDNA 
binding protein, TFAM, combined with EGFP (C57BL/6J-Tg(CAG-Tfam/EGFP)38Rin, 
Tfam/EGFP-Tg) (Fig. S1a).  Compared with wild-type mice, the Tfam/EGFP-Tg mice 
displayed 9.10-fold (heart) and 5.67-fold (kidney) levels of total Tfam mRNA, but the 
same levels of endogenous Tfam (Fig. S1b).  The TFAM/EGFP protein expression 
level was measured by Western blot using an antibody specific to GFP.  The left 
ventricle, kidney and pancreas had a relatively higher expression of TFAM/EGFP, but 
the spleen and stomach had low levels.  In Western blot analysis using cell 
fractionation of the heart and kidney, EGFP was detected in the mitochondrial fraction 
(Fig. S1c), and it was also found to be localized to the mitochondrial matrix using 
immunoelectron microscopy in the Tfam/EGFP-Tg mice (Fig. S1d).  A gel shift assay 
showed a band shift of a linear DNA fragment with an mtDNA sequence dependent on 
the concentration of TFAM and TFAM/EGFP proteins, indicating that the 
TFAM/EGFP protein had DNA binding capacity (Fig. S1e). 
We assayed the amount of mtDNA in 17 tissues from the Tfam/EGFP-Tg and 
wild-type mice using quantitative real-time PCR.  Compared with their wild-type 
littermates, most tissues of the Tfam/EGFP-Tg mice had increased mtDNA copy 
numbers: cerebral cortex (2.51- and 1.61-fold in female and male, respectively), 
cerebellum (1.59- and 1.34-fold), heart (2.32- and 2.03-fold), thymus (1.52- and 
2.67-fold), lung (4.28- and 2.43-fold), liver (0.92- and 1.03-fold), kidney (1.11- and 
1.32-fold), adrenal body (1.45- and 1.69-fold), spleen (2.02- and 0.69-fold), pancreas 
(1.89- and 1.45-fold), stomach (2.14- and 1.89-fold), small intestine (1.87- and 
1.60-fold), large intestine (2.09- and 1.06-fold), extensor digitorum longus (EDL) (2.83- 
and 1.90-fold), soleus (1.48- and 1.82-fold), ovary (1.59-fold), testis (1.10-fold) and tail 
(2.65- and 2.19-fold) (Fig. 1a).  There was no significant difference between the 
amount of mtDNA in the tails of the wild-type mice and those of mtGFP-Tg mice that 
expressed mitochondrial-targeted EGFP (data not shown) [24], suggesting that the 
increase in mtDNA in the Tfam/EGFP-Tg mice was due to the effect of the Tfam 
over-expression. 
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Analysis of mitochondrial disease symptoms in Tfam/EGFP over-expressing 
mito-mice 
To investigate whether over-expression of Tfam improves the mitochondrial disease 
phenotypes, Tfam/EGFP over-expressing mito-mice (Tg-mito-mice) were generated by 
in vitro fertilization.  Then the amounts of mtDNA in tail were estimated and we found 
that the Tg-mito-mice possessed 1.74 times as many as the average copy number of 
mtDNAs in their littermate mito-mice (Fig. 1b). 
Among several littermates of Tg-mito-mice and mito-mice, the mice with more than 
50% #mtDNA were examined for their survival.  Compared with mito-mice, the life 
spans of the Tg-mito-mice were significantly extended (P=0.01 in Mantel-Cox test), 
and the median survival periods were 54% prolonged, from 247 days in the mito-mice 
to 381 days in the Tg-mito-mice (Fig. 2a). 
Because most mito-mice show a high concentration of blood urea nitrogen (BUN) 
(reflecting renal dysfunction) and ultimately die due to renal failure [7], we measured 
the level of BUN in the mito-mice and Tg-mito-mice at eight months of age (Fig. 2b).  
An increased concentration of BUN was observed only in the mito-mice with more than 
65% #mtDNA in the tail, which was consistent with previous reports [7,23].  In the 
Tg-mito-mice group, the increase in BUN concentration was remarkably suppressed.  
However, there was one exception. A mito-mouse with 75.5% #mtDNA had a normal 
BUN concentration, and it had a 1.58 times as much mtDNA copy number as the 
average of the control mito-mice at four weeks of age.  These results indicate that the 
increased mtDNA copy number resulted in the recovery of kidney function.  The 
kidneys of mito-mice with more than 80% #mtDNA showed ischemia and increased 
size with a granulated surface [7].  In contrast, the Tg-mito-mouse kidney with 89% 
#mtDNA, which contained 2.99 times as many mtDNA copies compared to the 
mito-mouse control kidney, showed a mild enlargement with a normal surface (Fig. 2c; 
left panel).  A histological analysis showed dilatation of the cortical proximal and 
distal tubules in the renal tissues of the mito-mouse, which was recovered in the 
Tg-mito-mouse (Fig. 2c; right panels). 
 
Histochemical analyses of cytochrome c oxidase 
Histochemical staining was used to evaluate the COX activity in the kidney (Fig. 
3a) and heart (Fig. 3b).  The kidneys of mito-mice with 83% #mtDNA showed 
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dilation in the cortical proximal and distal tubules and a reduction of COX activity with 
a compensatory up-regulation of SDH activity [25].  The kidneys of the Tg-mito-mice 
with 89% #mtDNA, however, had recovered both the COX activity and the histological 
characteristics of these tissues. 
To confirm the effect of TFAM over-expression on the recovery of the 
mitochondrial activity in a single cell, cardiac muscle samples from the mito-mice and 
Tg-mito-mice (78% and 77%, respectively, &mtDNA in the heart tissue block) were 
subjected to histochemical and quantitative single-fiber PCR analyses.  Serial sections 
were used to compare the COX activity and proportion of #mtDNA in a single muscle 
fiber.  Consistent with a previous study [7], we found that there were fibers with 
variable proportions of #mtDNA in the mito-mouse heart and that COX-positive fibers 
exhibited less than 85% #mtDNA.  In contrast, there were COX-positive fibers with 
more than 85% &mtDNA in the Tg-mito-mouse heart (Fig. 3c).  Although it is difficult 
to estimate the amount of mtDNA in single fibers because there is no effective internal 
control, the elevation of the threshold percentage of the #mtDNA for maintaining COX 
activity was likely caused by the increase of mtDNA (2.27-fold higher than the 
mito-mouse control) due to the over-expression of TFAM. 
 
The expression of mitochondrial tRNA was increased in Tg-mito-mice 
In cells with #mtDNA, the amounts of mtDNA-coded proteins concurrently 
decreased regardless if the gene position was in the deleted region.  The decrease in 
mtDNA-coded proteins should be due to the shortage of tRNAs[9], and compensation 
for this shortage was thought to be responsible for prolongation of life span (Fig. 2a), 
improved kidney function (Fig. 2b, c) and COX activity (Fig. 3a, b) in Tg-mito-mice.  
Therefore, we examined the amount of tRNASer(AGY) that coded in the deleted region. 
Compared with mito-mouse tissues, the amounts of tRNASer(AGY) were increased as 
follows: 1.56-fold in the heart of the Tg-mito-mouse (78% #mtDNA), which contained 
2.27 times as many mtDNA copies as that of the mito-mouse (77%); 1.52-fold in the 
kidney of the Tg-mito-mouse (89%) which contained 2.99 times as many mtDNAs as 
that of the mito-mouse (83%); 2.42-fold in the soleus of the Tg-mito-mouse (70%) 
which contained 2.01 times as many mtDNAs as that of the mito-mouse (89%) (Fig. 4). 
The comparable result was observed using an additional set of mice (Fig. S2).  These 
results showed that the amount of tRNA was moderately restored in the Tg-mito-mouse, 
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although it did not completely recover. 
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Discussion 
 
In this study we showed that Tfam over-expression improved the symptoms caused 
by mitochondrial deficiency with large deleted mtDNA.  To elucidate the mechanism 
of this improvement, we created a new model for the pathogenicity of mutant mtDNA.  
The accumulation of #mtDNA causes the simultaneous decrease of wild-type mtDNA, 
and a reduction in the tRNA supply.  Consequently, the total protein levels of the 
respiratory complexes decrease as previously reported using cybrids with various 
proportions of #mtDNA [7].  A certain level of respiratory complexes is required to 
maintain normal activity, so a loss of mitochondrial function occurs when the wild-type 
mtDNA decreases below the threshold.  When the copy number of the wild-type 
mtDNA increases under the sufficient condition of gene expression, the tRNA supply 
and protein synthesis should increase, resulting in the improvement of mitochondrial 
function. 
It has been recognized commonly that the proportion of pathogenic mutant mtDNA 
is responsible for the occurrence of mitochondrial dysfunction.  However, our model 
proposes that the amount of wild-type mtDNA is important to maintain the 
mitochondrial function irrespective of the proportion of mutant mtDNA.  There was a 
strong correlation between the amount of wild-type mtDNA and the life spans of both 
mito-mice and Tg-mito-mice (Fig. S3), indicating that the amount of wild-type mtDNA 
directly affects the life span of these mice. 
However, there is a limitation for this therapeutic treatment.  In mito-mice, 
#mtDNA increases age-dependently [20], and mice born with a lower proportion of 
#mtDNA may develop the mitochondrial diseases within their life span.  In 
Tg-mito-mice, although the threshold percentage was elevated (Fig. 3c) by the increase 
in mtDNA levels, the mitochondrial dysfunction occurred when the proportion of 
#mtDNA exceeded the threshold level.  Thus, the mice could not be completely 
recovered even though the occurrence of the disease phenotype was extensively delayed 
and the life span was elongated (Fig. 2a). 
Considering the model further, the mtDNA up-regulating factor does not need to be 
applied with a transgenic technique in the zygote.  Viral vectors, gene guns or other 
undiscovered medicines might instead be used to increase the copy number of mtDNA.  
Furthermore, the method of increasing mtDNA copy number would be used to improve 
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mitochondrial dysfunction in adults.  There are several reports in which the copy 
number of mtDNA has been increased using a non-transgenic approach.  For instance, 
rats fed a high-fat diet and injected with heparin had increased levels of plasma free 
fatty acids and increased respiratory capacity, which is accompanied by an increase in 
the mtDNA copy number in skeletal muscle [26].  Raising the cytosolic Ca2+ with 
caffeine results in the increased expression of the peroxisome proliferative-activated 
receptor " coactivator-1! (PGC-1!) gene [27], which increases mitochondrial 
biogenesis by activating the expression of Tfam and the subunits of the respiratory chain.  
It has also been reported that several cytokines, such as IL-1' and combinations of 
TNF! and IL-1!, stimulate PGC-1! activity through the activation of p38 MAPK, 
which is accompanied by increased mitochondrial gene expression and cellular 
respiration [28].  Pursuing the mechanisms underlying these phenomena may provide 
clues for the discovery of potent medicines for the treatment of mitochondrial diseases. 
This is the first study to find that increase in the amount of total mtDNA rescues the 
impairment caused by pathogenic mtDNA, which is the cause of mitochondrial diseases.  
The therapeutic treatment in this study may be applied to human mitochondrial diseases, 
such as CPEO and KSS, especially in cases where the causal mtDNA mutation is the 
common deletion in which the deleted region extends from the mt-Atp8 to the mt-Nd5 
gene [29], which is the same as the #mtDNA in mito-mice. 
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Figure 1.  The effect of Tfam/EGFP over-expression on the amount of mtDNA.  (a) 
The amount of mtDNA in tissues of wild-type and Tfam/EGFP-Tg mice.  The vertical 
scales indicate the relative amounts of mtDNA compared with the mean of the 
wild-type samples in each sex.  The white bar, lighter dark bar, dark bar and black bar 
show wild-type females (n=10), Tg females (n=5), wild-type males (n=7) and Tg males 
(n=8), respectively.  *P < 0.05 and **P < 0.01.  (b) The amounts of total mtDNA in 
the tail of mito-mice and Tg-mito-mice were measured by the comparative real-time 
PCR method.  On average, the Tg-mito-mice contained 1.74 times as many mtDNA 
copies as the mito-mice in the four-week-old tail.  Both mouse strains had positive 
correlations between the proportion of #mtDNA and mtDNA copy number.  The solid 
and dashed lines indicate the regression lines for the mito-mice and Tg-mito-mice, 
respectively.
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Figure 2.  The effects of Tfam/EGFP over-expression on the disease phenotypes of 
mito-mice.  (a) Kaplan-Meier survival curves of mito-mice (n=9; blue line) and 
Tg-mito-mice (n=9; red line) with more than 50% #mtDNA.  (b) An association 
between the proportion of #mtDNA and blood urea nitrogen (BUN) in eight-month-old 
mice.  The black squares indicate Tg-mito-mice and the white squares indicate 
mito-mice.  (c; left panels) The morphology of the kidneys from a mito-mouse, a 
Tg-mito-mouse and a wild-type mouse at eight months of age.  The Tg-mito-mouse 
contained 2.99 times as many mtDNA copies in the kidney as the mito-mouse.  Bar, 5 
mm.  (c; right panels) The kidney sections were stained with hematoxylin and eosin to 
observe the histopathology of the renal cortex.  Bar, 0.1 mm. 
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Figure 3.  The tissue distribution of COX-positive and COX-negative cells in 
mito-mice and Tg-mito-mice.  (a, b) The tissue sections were sequentially stained for 
the activity of the COX (brown) and SDH (blue) of the electron transport chain.  The 
brown staining depicts cells with intact COX activity. The blue-stained cells have lost 
their COX activity but have retained SDH activity, which is only encoded by nuclear 
genes.  The mito-mouse and the Tg-mito-mouse displayed 83% and 89% #mtDNA in 
the kidney, respectively (a), and 78% and 77% in the heart, respectively (b).  The 
Tg-mito-mouse displayed 2.99 and 2.27 times as many mtDNA copies as the 
mito-mouse in the kidney and heart, respectively.  Bar, 100 µm in kidney and 50 µm in 
heart.  (c) The proportion of #mtDNA in a COX-positive single fiber of heart muscle. 
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Figure 4.  The amount of mitochondrial tRNASer(AGY) in heart, kidney and soleus 
measured by Northern blot analysis.  Relative amounts of tRNASer(AGY) compared with 
wild-type tissues are indicated.  The proportions of #mtDNA in each mouse were as 
follows: heart, 78% in Tg-mito-mouse and 77% in mito-mouse; kidney, 89% in 
Tg-mito-mouse and 82% in mito-mouse; and soleus, 70% in Tg-mito-mouse and 89% 
in mito-mouse. 
 
 
Supplementary Materials 
 
Figure Legends 
 
Figure S1.  Generation and characterization of Tfam/EGFP-Tg mice strain.  (a) 
Schematic structure of the transgene.  Mouse TFAM and EGFP cDNA were ligated 
and then introduced into a pCAGGS expression vector that contained the 
cytomegalovirus enhancer, the chicken !-actin promoter and the rabbit !-globin poly-A. 
The DNA fragment digested with SalI and StuI was isolated for microinjection.  (b) 
Real-time RT-PCR analysis of the expression of Tfam in wild-type (white bar, n=3) and 
Tfam/EGFP-Tg (gray bar, n=3) mice.  Glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) and 18S rRNA genes were used as the control in the Northern blot and the 
RT-PCR, respectively.  (c) Western blot analysis of cell fraction.  The mitochondrial 
fraction was determined by anti-TIM23 and anti-CO1 antibodies.  The TFAM/EGFP, 
which was detected with the anti-GFP antibody, was observed only in the mitochondrial 
fraction of the Tfam/EGFP-Tg mice.  (d) Immunoelectron micrographs of pancreases 
from Tfam/EGFP-Tg and wild-type mice.  The gold label for TFAM/EGFP was 
present in the mitochondria of the pancreas from the Tfam/EGFP-Tg mouse (white 
arrowhead), but not in that of the wild-type mouse.  Bar, 200 nm.  The rates of gold 
particles in the inner mitochondria were 66.7% (114/171 in Field of View) in the Tg 
mice and 3.3% (1/30 in FOV) in the wild-type mice (bar chart).  (e) Gel shift assay to 
assess DNA binding capacity of TFAM and TFAM/EGFP.  An 868-bp fragment of 
mtDNA (20 fmol) was incubated with increasing amounts of TFAM and TFAM/EGFP 
proteins. 
 
Figure S2.  The effect of Tfam over-expression on the mitochondrial transcription.  
The amounts of mitochondrial tRNASer(AGY) in heart and kidney were estimated by the 
Northern blot analysis. Compared to mito-mice (55.7% "mtDNA in 4-weeks tail), the 
Tg-mito-mouse (63.9%) possessed 1.21-fold (heart), 3.13-fold (kidney) higher in the 
levels of tRNASer(AGY). 
 
Figure S3.  The life span plotted with the amount of wild-type mtDNA.  The 
horizontal scale shows the relative copy number compared with the average amount of 
mtDNA of the mito-mice. 
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Materials and Methods 
 
Construction of the expression vector 
The signal sequence of mouse Tfam (GenBank Accession No. BC001987) was 
synthesized by PCR with primers 5#-GGC GAA TTC CTC GAG GCC ACC ATG GCG 
CTG TTC CGG GGA ATG T-3# and 5#-CAT ACG CGT ATG CTC AGA GAT GTC 
TCC GGA TCG T-3# using RT-PCR fragments derived from C57BL/6J (B6) as a 
template.  The coding region of EGFP was amplified by PCR with primers 5#- CAT 
ACG CGT ATG CTC AGA GAT GTC TCC GGA TCG T-3# and 5#-CAT ACG CGT 
ATG GTG AGC AAG GGC GAG GA-3# using the recombinant plasmid pEGFP-Tub 
(Clontech) as a template.  Both PCR products were digested with EcoRI and MluI, and 
the ligated pCAGGS expression vector [1] was digested with EcoRI. 
 
Generation of transgenic mice 
DNA fragments for transgenesis were removed by double digestion with SalI and 
StuI (Fig. 1a).  These fragments were separated by agarose gel electrophoresis from the 
cloning vector and then purified with a MonoFas DNA purification kit I (GL Science).  
The purified DNA fragments were injected into the pronuclei of the fertilized mouse 
(B6) oocytes according to the standard procedure [2].  To identify the transgenic mice, 
genomic DNA were prepared from the tails using a Gentra Puregene Tissue kit 
(QIAGEN) and two sets of primer pairs, (A) 5#-GCT CTA GAG CCT CTG CTA 
ACC-3#, 5#-TGA ACA GCT CCT CGC CCT TGC TC-3# and (B) 5#-TGA GCA AAG 
ACC CCA ACG AGA AGC-3#, 5#-TTA GCC AGA AGT CAG ATG CTC AAG-3#, 
were synthesized to amplify the PCR fragments (258 and 248 bp) specific to the EGFP 
sequence [3]. 
 
Preparation of total RNA from mice tissues 
Tails (about 5-mm lengths), hearts, kidneys and skeletal muscle samples for RNA 
preparation were cut and immediately frozen in liquid nitrogen.  The frozen samples 
were crushed and homogenized (SK-100, Tokken). Then, the total RNA was isolated 
using the ISOGEN (NIPPON GENE) or QIAeasy plus (QIAGEN) kits. 
 
Real-time RT-PCR analysis of Tfam mRNA 
A One Step SYBR RT-PCR Kit (TaKaRa) and the following primer sets were used 
for real-time RT-PCR; Tfam: TaKaRa MA027412 (primer set 1), TaKaRa MA076007 
(primer set 2) (the set was designed in the 3’ UTR region of the Tfam sequence), Rps18: 
TaKaRa 050364. 
 
Preparation of the mitochondrial fraction 
Sixty milligrams of fresh kidneys were used to prepare the cytosol and 
mitochondrial fraction.  The samples were homogenized with Tissue-Ruptor 
(QIAGEN) for 10 seconds followed by a Qproteome Mitochondria Isolation Kit 
(QIAGEN) treatment. 
 
Western blot analysis 
Proteins from the tissue samples were separated by SDS-PAGE and transferred onto 
a PVDF membrane (GE Healthcare).  After being blocked with 5% BSA in TBS for 
!-Actin or 0.5% skim milk for others, the membranes were incubated with a specific 
antibody (anti-GFP: MBL, anti-CO1 and anti-!-Actin: Abcam, anti-TIM23: BD).  
Horseradish peroxidase-conjugated goat antibody to rabbit IgG (Bio-Rad) or mouse IgG 
(Abcam) was used as a secondary antibody.  Immun-Star HRP Substrate (Bio-Rad) 
was used for the detection. 
 
Immunogold electron microscopy 
The pancreas and EDL of Tfam/EGFP-Tg or wild-type mice were fixed with a 
solution containing 4% paraformaldehyde and 0.2% glutaraldehyde in a 0.1 M 
phosphate buffer (pH 7.4) for 60 min at 4°C.  The tissues were washed with PBS five 
times, dehydrated with a graded ethanol series, embedded in LR White and finally 
polymerized with UV light at -20°C, as reported previously [4].  Ultra-thin sections of 
LR White-embedded samples were prepared and mounted on nickel grids.  After being 
blocked with 0.5% BSA in PBS for 15 min, the sections were incubated with a rabbit 
anti-GFP antibody (1:1,000; MBL, Japan) overnight at 4°C.  The sections were 
washed with PBS and incubated with a goat anti-rabbit IgG coupled to 15-nm colloidal 
gold (1:50; BioCell Research Laboratories, Cardiff, UK) for 60 min at room 
temperature.  For the control experiments, non-immune normal rabbit IgG and the 
immunogold were used.  After being washed with PBS and distilled water, all sections 
were stained with uranyl acetate and lead citrate and then examined in a JEM 1230 
transmission electron microscope (JEOL, Tokyo, Japan) at an accelerating voltage of 80 
kV. 
 
DNA Binding Assay 
DNA fragments that encode TFAM and TFAM/EGFP with a 6$His-tag at the 
C-terminus were generated and cloned into the vector pCAGGS.  The recombinant 
proteins were expressed in COS7 cells and purified using the Ni-NTA Spin Kit 
(QIAGEN).  
The 868 bp fragment of mtDNA was amplified using primer pairs 5’- AAA AAG 
ATA AAA GGA ACT CGG CAA ACA AGA-3’ and 5’- ATA AAG AAC ACT ATT 
AGG GAG AGG ATT TGA-3’.  The fragment (20 fmol) was incubated with 
increasing concentrations (5-80 pmol) of TFAM or TFAM/EGFP proteins in a binding 
buffer (150 mM KCl, 0.1 mM dithiothreitol, 0.1 mM EDTA, 10 mM Tris, pH 7.4), 
which was contained in the Electrophoretic Mobility Shift Assay Kit (Molecular 
Probes).  The reaction mixtures were incubated for 20 min at room temperature and 
subsequently analyzed by electrophoresis in a 1% agarose gel with 1xTBE. The 
fragment of mtDNA in the gel was detected using a SYBR Green EMSA nucleic acid 
gel stain. 
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